Keywords: genentech, herceptin, survival, benefit, hoffmann-la, roche, trastuzumab

Genentech's Herceptin has survival benefit

Article | 19 October 2000

Genentech and Hoffmann-La Roche's Herceptin (trastuzumab) improvedsurvival by 45% among HER-2 positive breast cancer patients when used in combination with chemotherapy, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Genentech

Roche

Go to company listing

Related Drugs

Herceptin

trastuzumab

Go to drug listing